Nerispirdine (HP184) ( DrugBank: Nerispirdine )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
13	多発性硬化症／視神経脊髄炎	2

13. 多発性硬化症／視神経脊髄炎

---

臨床試験数 : 3,342 /  薬物数 : 2,355 - (DrugBank : 406) / 標的遺伝子数 : 269 - 標的パスウェイ数 : 241

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00811902 (ClinicalTrials.gov)	December 2008	18/12/2008	Efficacy, Safety, and Tolerability of Nerispirdine in Patients With Multiple Sclerosis	A 14-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Nerispirdine 50 mg, 100 mg, and 200 mg in Patients With Multiple Sclerosis.	Multiple Sclerosis	Drug: Nerispirdine (HP184);Drug: placebo	Sanofi	NULL	Completed	18 Years	N/A	Both	405	Phase 2	United States;Canada;Finland;France;Germany;Norway;Spain
2	NCT00772525 (ClinicalTrials.gov)	September 2008	13/10/2008	Single Oral Doses Study of Nerispirdine on Visual Function in Patients With Multiple Sclerosis	A Double-blind, Placebo-controlled, Randomized Crossover, Activity Study of Single Oral Doses of 50 mg and 400 mg Nerispirdine on Visual Function in Patients With Multiple Sclerosis	Multiple Sclerosis;Optic Nerve;Neuritis	Drug: Nerispirdine (HP184);Drug: Placebo	Sanofi	NULL	Completed	18 Years	N/A	Both	31	Phase 2	United States